Company CEO purchases 2,873 shares

In a recent transaction, Scott M Brinker, the President and CEO of $DOC, acquired 2,873 shares of the company on 07-28-2025 for an approximate total of $49,990. This purchase, as detailed in a recent SEC filing reviewed by Quiver Quantitative, resulted in a 1.4% increase in their ownership of this particular class of $DOC stock, bringing their total holdings to 207,486 shares.

Over the last six months, insiders at $DOC have engaged in 11 transactions involving the company’s stock on the open market. Notably, all 11 of these transactions have been purchases with no sales recorded. Scott M Brinker, the President and CEO, in particular, has made three purchases, acquiring a total of 16,960 shares at an estimated cost of $298,250. Other notable insider purchases include Katherine M Sandstrom with 11,288 shares, Tommy G Thompson with 11,477 shares, Sara Grootwassink Lewis with 6,000 shares, Ava Lias-Booker with 5,000 shares, John T Thomas with 4,200 shares, and Pamela Shelley-Kessler with 2,838 shares.

In terms of hedge fund activity relating to $DOC, 383 institutional investors have added shares of the company’s stock to their portfolios, while 335 have reduced their positions in the most recent quarter. Among the significant moves made by these institutional investors were UBS AM, a distinct business unit of UBS Asset Management Americas LLC, adding 7,872,150 shares (+584.6%) in Q1 2025, totaling approximately $159,174,873. Conversely, Long Pond Capital, LP removed 4,286,388 shares (-100.0%) from their portfolio during the same period, amounting to around $86,670,765.

Moreover, congressional stock trading data reveals that members of Congress have conducted two transactions involving $DOC shares within the last six months. These transactions consisted of two sales by Representative Robert Bresnahan and Representative Julie Johnson, with each selling up to $15,000 worth of the stock on different dates earlier in the year.

Specific to $DOC, Wall Street analysts have recently provided insights into the company’s performance. Notably, four firms have issued buy ratings for the stock, while no sell ratings have been reported. Analysts from Argus Research, Baird, Evercore ISI Group, and Wedbush, among others, have all issued positive outlooks on $DOC, indicating strong performance potential in the market.

In addition to analyst ratings, several analysts have put forth price targets for $DOC in recent months. With a median target of $21.5, analysts like Nicholas Yulico, Connor Siversky, John Staszak, Amanda Sweitzer, James Kammert, and Richard Anderson have all offered varying price targets for the stock, reflecting their optimism regarding its future performance.